ABBV-3373 Shows Promise for Rheumatoid Arthritis (RA), Phase 2a Data Shows
A Phase 2a study sought to compare the safety, efficacy, and tolerability of ABBV-3373, as compared to adalimumab, for patients with rheumatoid arthritis (RA). Patients involved in the study had…